Pharmacokinetic and metabolomic analyses of Mangiferin calcium salt in rat models of type 2 diabetes and non-alcoholic fatty liver disease
Tóm tắt
Non-alcoholic fatty liver is one of the most common comorbidities of diabetes. It can cause disturbance of glucose and lipid metabolism in the body, gradually develop into liver fibrosis, and even cause liver cirrhosis. Mangiferin has a variety of pharmacological activities, especially for the improvement of glycolipid metabolism and liver injury. However, its poor oral absorption and low bioavailability limit its further clinical development and application. The modification of mangiferin derivatives is the current research hotspot to solve this problem. The plasma pharmacokinetic of mangiferin calcium salt (MCS) and mangiferin were monitored by HPLC. The urine metabolomics of MCS were conducted by UPLC-Q-TOF-MS. The pharmacokinetic parameters of MCS have been varied, and the oral absorption effect of MCS was better than mangiferin. Also MCS had a good therapeutic effect on type 2 diabetes and NAFLD rats by regulating glucose and lipid metabolism. Sixteen potential biomarkers had been identified based on metabolomics which were related to the corresponding pathways including Pantothenate and CoA biosynthesis, fatty acid biosynthesis, citric acid cycle, arginine biosynthesis, tryptophan metabolism, etc. The present study validated the favorable pharmacokinetic profiles of MCS and the biochemical mechanisms of MCS in treating type 2 diabetes and NAFLD.
Từ khóa
Tài liệu tham khảo
Pinchevsky Y, et al. Demographic and clinical factors associated with development of type 2 diabetes: a review of the literature. Int J Gen Med. 2020;13:121–9.
Kumar R, Priyadarshi RN, Anand U. Non-alcoholic fatty liver disease: growing burden, adverse outcomes and associations. J Clin Transl Hepatol. 2020;8(1):76–86.
Ke W, et al. Dietary Platycodon grandiflorus Attenuates Hepatic Insulin Resistance and Oxidative Stress in High-Fat-Diet Induced Non-Alcoholic Fatty Liver Disease. Nutrients. 2020;12(2):480.
Tuong TTK, et al. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan. Diagnostics (Basel). 2020;10(3):159.
Matsuzaka T, Shimano H. A new perspective on type 2 diabetes, dyslipidemia, and non-alcoholic fatty liver disease. J Diabetes Investig. 2020;11(3):533–4.
Saponaro C, Gaggini M, Gastaldelli A. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. Curr Diab Rep. 2015;15(6):607.
Cusi K. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia. 2016;59(6):1112–20.
Tao Z, et al. High-fat diet from perilla oil induces insulin resistance despite lower serum lipids and increases hepatic fatty acid oxidation in rats. Lipids Health Dis. 2014;13:15.
Byeon SK, et al. High-throughput and rapid quantification of lipids by nanoflow UPLC-ESI-MS/MS: application to the hepatic lipids of rabbits with nonalcoholic fatty liver disease. Anal Bioanal Chem. 2016;408(18):4975–85.
Sun R, et al. Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model. Biomed Pharmacother. 2020;123:109721.
Soder J, et al. Indication of metabolic inflexibility to food intake in spontaneously overweight Labrador retriever dogs. BMC Vet Res. 2019;15(1):96.
Dhibi M, et al. The intake of high fat diet with different trans fatty acid levels differentially induces oxidative stress and non alcoholic fatty liver disease (NAFLD) in rats. Nutr Metab. 2011;8:65.
Chai SY, et al. Differential patterns of insulin secretion and sensitivity in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease versus patients with type 2 diabetes mellitus alone. Lipids Health Dis. 2014;13:7.
Imran M, et al. Mangiferin: a natural miracle bioactive compound against lifestyle related disorders. Lipids Health Dis. 2017;16(1):84.
Rasool M, et al. Mangiferin, a natural polyphenol protects the hepatic damage in mice caused by CCl4 intoxication. Comp Clin Pathol. 2011;21(5):865–72.
Marquez L, et al. Mangiferin decreases inflammation and oxidative damage in rat brain after stress. Eur J Nutr. 2012;51(6):729–39.
Li HW, et al. Protective effects of mangiferin in subchronic developmental lead-exposed rats. Biol Trace Elem Res. 2013;152(2):233–42.
Liu YW, et al. Suppression of methylglyoxal hyperactivity by mangiferin can prevent diabetes-associated cognitive decline in rats. Psychopharmacology. 2013;228(4):585–94.
Du S, et al. Mangiferin: an effective therapeutic agent against several disorders (review). Mol Med Rep. 2018;18(6):4775–86.
Szandruk M, Merwid-Lad A, Szelag A. The impact of mangiferin from Belamcanda chinensis on experimental colitis in rats. Inflammopharmacology. 2018;26(2):571–81.
Kammalla AK, et al. Comparative pharmacokinetic study of mangiferin after oral administration of pure mangiferin and US patented polyherbal formulation to rats. AAPS PharmSciTech. 2015;16(2):250–8.
Liu M, et al. Solubility, Antioxidation, and Oral Bioavailability Improvement of Mangiferin Microparticles Prepared Using the Supercritical Antisolvent Method. Pharmaceutics. 2020;12:2.
Xu G; Hainan Deze Pharmaceutical Research Co., Ltd. Mangiferin Salt and Method of Preparing the Same and Use Thereof. CN101108869B; 2008.
Telang M, et al. Therapeutic and cosmetic applications of mangiferin: a patent review. Expert Opin Ther Patents. 2013;23(12):1561–80.
Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol. 2009;46(2):113–8.
LIN H, et al. Effect of Mangiferin calcium salt on type 2 diabetes mellitus and nonalcoholic fatty liver in rats. Chinese J Clin Pharmacol. 2018;34(13):1543–6.
Apontes P, et al. Mangiferin stimulates carbohydrate oxidation and protects against metabolic disorders induced by high-fat diets. Diabetes. 2014;63(11):3626–36.
YANG C-Q, et al. Mangiferin ameliorates insulin resistance by inhibiting inflammation and regulatiing adipokine expression in adipocytes under hypoxic condition. Chin J Nat Med. 2017;15(9):0664–73.
Costes S. Targeting protein misfolding to protect pancreatic beta-cells in type 2 diabetes. Curr Opin Pharmacol. 2018;43:104–10.
Wang HL, et al. Mangiferin facilitates islet regeneration and beta-cell proliferation through upregulation of cell cycle and beta-cell regeneration regulators. Int J Mol Sci. 2014;15(5):9016–35.
Zhou L, et al. Mitigation of insulin resistance by Mangiferin in a rat model of fructose-induced metabolic syndrome is associated with modulation of CD36 redistribution in the skeletal muscle. J Pharmacol Exp Ther. 2016;356(1):74–84.
Xing X, et al. Mangiferin treatment inhibits hepatic expression of acyl-coenzyme a:diacylglycerol acyltransferase-2 in fructose-fed spontaneously hypertensive rats: a link to amelioration of fatty liver. Toxicol Appl Pharmacol. 2014;280(2):207–15.
Khurana RK, et al. Improving the biopharmaceutical attributes of mangiferin using vitamin E-TPGS co-loaded self-assembled phosholipidic nano-mixed micellar systems. Drug Deliv Transl Res. 2018;8(3):617–32.
Quadri F, Telang M, Mandhare A. Therapeutic and cosmetic applications of mangiferin: an updated patent review (patents published after 2013). Expert Opin Ther Pat. 2019;29(6):463–79.
Na LX, et al. Curcumin improves insulin resistance in skeletal muscle of rats. Nutr Metab Cardiovasc Dis. 2011;21(7):526–33.
Zhang Q, et al. Mangiferin improved Palmitate-induced-insulin resistance by promoting free fatty acid metabolism in HepG2 and C2C12 cells via PPARalpha: Mangiferin improved insulin resistance. J Diabetes Res. 2019;2019:2052675.
Wang C, et al. The compound of Mangiferin-Berberine salt has potent activities in modulating lipid and glucose metabolisms in HepG2 cells. Biomed Res Int. 2016;2016:8753436.
Wang H, et al. Mangiferin ameliorates fatty liver via modulation of autophagy and inflammation in high-fat-diet induced mice. Biomed Pharmacother. 2017;96:328–35.
Li J, et al. Mangiferin improves hepatic lipid metabolism mainly through its metabolite-Norathyriol by modulating SIRT-1/AMPK/SREBP-1c signaling. Front Pharmacol. 2018;9:201.
Stanford KI, Goodyear LJ. Exercise and type 2 diabetes: molecular mechanisms regulating glucose uptake in skeletal muscle. Adv Physiol Educ. 2014;38(4):308–14.
Oxenkrug G. Insulin resistance and Dysregulation of tryptophan–Kynurenine and Kynurenine–Nicotinamide adenine dinucleotide metabolic pathways. Mol Neurobiol. 2013;48(2):294–301.
Mazur-Bialy AI, Pochec E. Riboflavin Reduces Pro-Inflammatory Activation of Adipocyte-Macrophage Co-culture. Potential Application of Vitamin B2 Enrichment for Attenuation of Insulin Resistance and Metabolic Syndrome Development. Molecules. 2016;21:12.
Zhou SS, et al. B-vitamin consumption and the prevalence of diabetes and obesity among the US adults: population based ecological study. BMC Public Health. 2010;10:746.
ARUOMA OI, et al. The antioxidant action of taurine, hypotaurine and their metabolic precursors. Biochem J. 1988;256:251–5.
Casquel De Tomasi L, et al. Pathological hypertrophy and cardiac dysfunction are linked to aberrant endogenous unsaturated fatty acid metabolism. PLoS One. 2018;13(3):e0193553.
GEMPEL K, et al. Screening for carnitine palmitoyltransferase II deficiency by tandem mass spectrometry. J Inherit Metab Dis. 2002;25:17–27.
SHEN JJ, et al. Acylcarnitines in fibroblasts of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and other fatty acid oxidation disorders. J Inherit Metab Dis. 2000;23:27–44.
Spiekerkoetter U, et al. Changes in blood carnitine and acylcarnitine profiles of very long-chain acyl-CoA dehydrogenase-deficient mice subjected to stress. Eur J Clin Investig. 2004;34:191–6.
Yuan W, et al. Amine metabolomics of hyperglycemic endothelial cells using capillary LC-MS with isobaric tagging. J Proteome Res. 2011;10(11):5242–50.
Platten M, et al. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019;18(5):379–401.
Murakami S. Role of taurine in the pathogenesis of obesity. Mol Nutr Food Res. 2015;59(7):1353–63.
Mortada I. Hyperuricemia, type 2 diabetes mellitus, and hypertension: an emerging association. Curr Hypertens Rep. 2017;19(9):69.